X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.fiercepharma.com/pharma/sage-highly-encouraged-biogen-partnered-zurzuvae-stops-short-offering-sales-projection
https://www.globenewswire.com//news-release/2023/12/14/2796102/0/en/ZURZUVAE-zuranolone-CIV-a-Landmark-Oral-Treatment-for-Women-with-Postpartum-Depression-PPD-is-Now-Available-in-the-U-S.html
https://www.fiercepharma.com/pharma/sage-biogen-will-charge-15900-postpartum-depression-drug-zurzuvae
https://www.biopharmadive.com/news/sage-depression-drug-fda-review-documents-zurzuvae-safety/692625/
https://endpts.com/sage-shrinks-workforce-by-40-in-light-of-major-depression-drug-rejection/
https://www.biopharmadive.com/news/sage-biogen-zuranolone-launch-depression-partnership/690111/
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-biogen-sage-therapeutics-pill-clinical-depression-2023-08-04/
https://endpts.com/fda-says-no-adcomm-planned-for-biogen-sages-depression-drug/
https://www.fiercebiotech.com/biotech/eliem-drops-depression-drug-ending-pursuit-biogen-sage-and-lays-55-team-stretch-cash-2027
https://investors.biogen.com/news-releases/news-release-details/biogen-and-sage-therapeutics-announce-fda-accepts-filing-new
https://www.fiercebiotech.com/biotech/jpm23-sage-ceo-says-post-partum-depression-no-niche-zuranolone-aims-fill-gaps-depression
https://investors.biogen.com/news-releases/news-release-details/biogen-and-sage-therapeutics-complete-rolling-submission-new
https://endpts.com/ahead-of-fda-filing-sage-and-biogen-tout-more-data-in-hopes-of-alleviating-durability-concerns/
https://www.reuters.com/article/us-sage-biogen-study/sage-biogens-drug-meets-main-goal-in-postpartum-depression-study-idUSKBN2NI2ZP
https://www.fiercebiotech.com/biotech/sage-biogen-ship-depression-med-fda-rolling-submission
https://news.yahoo.com/sage-biogens-depression-drug-meets-124008275.html
https://www.fiercepharma.com/marketing/abbvie-s-vraylar-turns-mixed-results-depression-but-pharma-decides-to-file-for-approval
https://www.businesswire.com/news/home/20211019005298/en/Sage-Therapeutics-and-Biogen-Announce-Plans-to-Submit-a-New-Drug-Application-NDA-for-Zuranolone-to-the-U.S.-Food-Drug-Administration-in-the-Second-Half-of-2022-with-Rolling-Submission-Expected-to-Start-in-Early-2022
https://www.biopharmadive.com/news/biogen-sage-depression-drug-deal-zuranolone/589772/
https://www.fiercebiotech.com/biotech/sage-shares-data-retreatment-depression-drug-zuranolone#:~:text=Sage%20said%2055.5%25%20of%20those,one%20or%20two%20courses%2C%20though.
https://www.biopharmadive.com/news/sage-restructuring-layoffs-340-employees/575641/
https://www.biopharmadive.com/news/sage-restructuring-layoffs-340-employees/575641/
https://www.fiercebiotech.com/biotech/sage-to-run-3-new-studies-to-save-once-failed-depression-drug
https://endpts.com/sage-confirms-suspension-of-2-depression-trials-after-phiii-flop-esperion-follows-up-maiden-approval-with-combo-ok/
https://www.biopharmadive.com/news/jp-morgan-biotech-winners-losers-2019/545818/
https://endpts.com/sages-oral-ppd-drug-ticks-efficacy-safety-boxes-in-key-trial-easing-fears-of-fainting-risk/
https://www.reuters.com/article/us-sage-study/sage-shares-soar-after-oral-postpartum-depression-treatment-succeeds-in-trial-idUSKCN1P10WA?feedType=RSS&feedName=healthNews
https://endpts.com/sage-shrugs-off-potential-competition-in-postpartum-depression/
https://endpts.com/sage-appears-set-for-a-breakthrough-fda-ok-on-postpartum-depression-drug-but-whos-going-to-use-it/
https://www.biospectrumasia.com/news/25/11099/sage-therapeutics-shionogi-ink-deal-for-mdd-treatment-.html
https://endpts.com/on-a-roll-sage-grabs-a-575m-deal-on-limited-asian-rights-to-sage-217-a-potential-gamechanger-in-depression/
https://www.cnbc.com/2018/06/12/sage-shares-up-after-fda-allows-expedited-depression-drug-development.html
https://endpts.com/with-a-big-assist-from-the-fda-sage-plots-a-swift-march-through-phiii-for-oral-depression-drug/
https://seekingalpha.com/article/4137580-sages-antidepressant-franchise-make-acquisition-target
https://www.biospace.com/article/exclusive-sage-therapeutics-looks-to-file-nda-for-postpartum-depression-treatment-later-this-year/
https://www.cnbc.com/2017/11/10/sage-pharmaceuticals-stock-up-after-successful-trials-for-postpartum-depression-drug.html
http://www.fiercebiotech.com/biotech/sage-soars-small-post-partum-depression-study-results
Market Place
Share 
